VISUAL ABSTRACTHartman
Europe (1) . Acute decompensated HF is the most common reason for HF hospitalization (3) . Of those hospitalized, 50% are readmitted within 6 months, and 17% to 45% die within 1 year of initial admission (1, 4) . The median length of stay is 4 to 20 days, and the inpatient mortality rate is 4% to 30% (2) .
There have been no major advances in therapies for acute HF (AHF) in recent decades, and current therapies have substantial limitations. Diuretics, although a cornerstone of AHF management, offer no direct myocardial effects and are known to cause electrolyte abnormalities and metabolic disturbances.
Inotropes are associated with arrhythmias and increased mortality, and pure vasodilators can cause systemic hypotension (5) (6) (7) (8) (9) . Thus, there is a need for new therapies that safely and effectively reduce cardiac load while enhancing cardiac output (CO).
Accomplishing the latter safely has proven difficult because of the frequent reliance on therapies that are cyclic adenosine monophosphate (cAMP) stimulators, which are fraught with undesirable complications (5, (9) (10) (11) .
Nitroxyl (HNO) donors are a class of molecules with unique biochemical and pharmacological properties that have been investigated over several years for their potential therapeutic applications. Although related to nitric oxide (NO), the pharmacological effects of HNO are different from NO; these effects produce arterial and venous dilation, as well as direct, beneficial, cAMP/protein kinase Aindependent lusitropic and inotropic effects, in both the normal and failing myocardium (8, 10, 12, 13) . HNO enhances sarcoplasmic reticular calcium uptake and release through modulation of sarcoplasmic reticulum calcium 2þ adenosine triphosphatase (SERCA2a), phospholamban (PLN), and the ryanodine receptors.
HNO donors also improve myofilament calcium sensitivity without affecting the L-type calcium channel or total sarcoplasmic reticular calcium content (8, 10, (14) (15) (16) (17) . (12, (18) (19) (20) . However, although it produces vasodilation and cAMP-independent inotropic and lusitropic effects in dogs, it is chemically unstable and not suitable for clinical use (18, 19, 21) . CXL-1020 was a first-generation pure HNO donor (i.e., it did not generate nitrite in addition to HNO upon decomposition, but an inactive organic by-product, CXL-1051) and was shown to produce beneficial vasodilatory, inotropic, and lusitropic effects in normal and HF animal models; however, due to injection-site toxicity, its development was halted (8, 11 Doppler studies were performed to determine LV fractional area shortening (LVFAS), LV end-diastolic circumferential wall-stress (LVEDWS), the ratio of early-to-late filling time integrals (Ei/Ai), and deceleration time (DT) of early mitral valve inflow velocity. With the 0.7-and 7-mg/kg/min infusions, myocardial oxygen consumption (MVO 2 ) was assessed as described previously (8, 28) , at baseline and again at 2 and 4 h (see Supplemental Material).
Electrocardiography (ECG) was used to assess the QT interval throughout the study for determination of heart rate (HR).
As described previously (8) The T-statistic for 2 independent means was used to compare treatment effects (p < 0.05).
SVT and VF threshold scores with BMS-986231 7
mg/kg/min and vehicle were compared using the Student paired t-test (p < 0.05). At 4 h, BMS-986231 was associated with significant increases of 41% to 80% in the Ei/Ai ratio from baseline; a significant increase in DT from baseline across all doses was also seen ( Table 1 , Figure 1C ). The effects on Ei/Ai ratio ( Figure 1D ) and DT were sustained through the 1-h washout period. A significant decrease in LVEDWS versus baseline over 4 h was also observed (À12% to À19%) (Table 1, Figure 1C ). There was no significant dose dependency for these endpoints. HR was not significantly affected by BMS-986231 infusion, regardless of dose (p ¼ NS) ( Table 1) .
RESULTS

GROUP
BMS-986231 resulted in a numerically but nonstatistically significant reduction in SAP, and a drop in MAP that reached significance with the 7-mg/kg/ min dose infusion (À11%) ( Table 1) . SVR was significantly reduced versus baseline across all doses at 4 h (À15% to À23%), with significant reductions also seen for all doses at the 1-and 2-h intervals ( Table 1 For the 4-h study, blood levels of BMS-986231
(and its principal, inactive by-product BMT-284730) with the 0.7-and 2-mg/kg/min doses accumulated between 2 and 4 h ( Table 2) . With the 7-mg/kg/min dose infusion, 2-and 4-h levels of BMS-986231 were equivalent, whereas BMT-284730 levels continued to accumulate. At 1 h post-infusion, BMS-986231 levels were 70% to 80% lower across all doses than at 4 h;
BMT-284730 levels were maintained at 1 h postinfusion ( Table 2) . mg/kg/min over 2 h in the 7 dogs that underwent PVS were broadly similar to those seen in the doseescalation component of the study (Table 3) . LVESV was significantly decreased, with little effect on LVEDV. Significant increases versus baseline were seen in LVEF, LVFAS, SV, and CO ( Table 3) . There was no significant change in HR with BMS-986231 versus baseline, and there was minimal effect on SAP and MAP. Vehicle administration was not associated with any effect on blood pressure or HR, and also had no effect on LV functional measures.
During PVS, BMS-986231 increased the mean threshold score for SVT or VF 2-fold versus vehicle (18 vs. 9) and had no impact on subsequent cardioversion to restore sinus rhythm. Subsequently, all animals were successfully cardioverted. Table 4) .
With BMS-986231 50 mg/kg/min, significant reductions in LVEDP and LVEDV (À63% and À6%, respectively) were seen after 3 h of infusion ( Table 4) .
LVEF increased significantly and progressively during the infusion (þ12% after 3 h), and this improvement Hartman et al.
was maintained with HEX ( Table 4 , Figure 2A ). SV and CO were preserved after 3 h, although moderate but significant reductions in both parameters were seen 1 h into the infusion. However, when preload was restored with HEX, both SV and CO were significantly increased above baseline ( Table 4 , Figure 2A ).
BMS-986231 50 mg/kg/min was associated with significant time-dependent enhancement in loadindependent indexes of contractility ( Figure 3A) , which increased the slopes of both ESPVR (þ19%) and PRSW (þ12%) ( Table 4 , Figure 2A ), even after preload was acutely restored (þHEX). Representative LV pressure-volume families also showed typical inotropic leftward shifts with BMS-986231 ( Figure 3B ).
The load-dependent index, LV peak þdP/dt, was also significantly increased (þ14%) after 3 h ( Table 4) .
Both Tau and the slope of the EDPVR were significantly reduced versus baseline with BMS-986231 50 mg/kg/min (À6% and À28%, respectively) ( Table 4) . A significant reduction in Tau was seen 30 min postinfusion start (data not shown), and was sustained throughout the infusion period.
With BMS-986231 50 mg/kg/min, there was a maximal but clinically insignificant reduction in HR of 4% during this period ( Table 4 , Figure 2A ). MAP was reduced by 14%; this effect was both rapid and sustained ( Figure 2A) . After 3 h, both SVR and Ea were also significantly reduced versus baseline (À16% and À23%, respectively). HEX had negligible effects on PRSW, EDPVR, and HR.
BMS-986231 was also associated with significant reductions in LVSW and PVA after 3 h (À11% and À25% vs. baseline, respectively). The reduction in PVA was preserved with HEX ( Figure 2A) , suggesting a reduction in MVO 2 .
D o g s w i t h p a c i n g -i n d u c e d c a r d i o m y o p a t h y ( B 2 ) . Pacing resulted in severely depressed LV
function and ventricular modeling ( Table 4) . Mean LVEDP was elevated, and the LV peak þdP/dt was decreased; MAP and HR were within normal limits.
Similarly, the Ea, LVEF, and slopes for PRSW and EDPVR post-pacing were consistent with HFassociated cardiac and vascular dysfunction.
In these paced dogs, BMS-986231 was associated with significant and dose-dependent decreases in filling and (albeit more moderate) systemic pressures.
For instance, following 3 h of infusion, LVESP and LVEDP were significantly reduced (LVESP: À8 to À17%; LVEDP: À14 to À24%; all p < 0.05 vs. baseline) ( Table 4) .
BMS-986231 was also associated with significant
reductions in LVEDV at 3 h (À4 to À9%) ( Table 4) .
Compared with baseline, LVEF increased dose dependently by 23% to 41% (all p < 0.05) at 3 h. SV and CO also displayed dose-dependent increases versus baseline ( Table 4 , Figure 2B ). These increases in LVEF, SV, and CO were sustained at 1 h postinfusion (data not shown).
All load-independent indexes of contractility also improved in the paced dogs during infusion. The EDPVR, mm Hg/ml 1 AE 0.1 0.8 AE 0.1* (À28 AE 7) 0.9 AE 0.2* (À18 AE 9) 3 AE 0.4 (25)
Values shown are mean AE SEM or mean AE SD (n). *p < 0.05 vs. respective baseline value. †p < 0.05 vs. 25 mg/kg/min dose. ‡p < 0.05 vs. 50 mg/kg/min (3 h). §mm Hg Â ml/ml.
Ea ¼ arterial elastance; EDPVR ¼ end-diastolic pressure-volume relationship; ESPVR ¼ end-systolic pressure-volume relationship; HEX ¼ Hextend (plasma volume-expanding solution); LVESP ¼ LV end-systolic pressure; PRSW ¼ preload-recruitable stroke work; PVA ¼ pressure-volume area; SW ¼ stroke work; Tau ¼ LV relaxation time-constant; other abbreviations as in Tables 1 and 3. slopes of the ESPVR and PRSW increased progressively and dose dependently over the 3-h infusion (e.g., ESPVR: þ11% to þ29%; PRSW: þ10% to þ22%; all p < 0.05 vs. baseline) (Table 4, Figure 2B , Figures 4A,   and 4B) . Increases in the slopes of both PRSW and ESPVR were sustained 1 h after infusion (data not shown).
After the 3-h infusion period, Tau was reduced by 18% (25 mg/kg/min), 14% (50 mg/kg/min), and 16% (75 mg/kg/min) (all p < 0.05) versus baseline. The estimated EDPVR was dose-dependently reduced by 17% to 39% (all p < 0.05) versus baseline (Table 4, Figure 2B ). These diastolic improvements were partially sustained for both indexes at all doses 1 h after infusion (data not shown).
HR was marginally reduced versus baseline after 3 h, reaching statistical significance with the 25-and 75-mg/kg/min doses (À5% and À6%, respectively) (Table 4, Figure 2B ). Ea and SVR were also significantly reduced after 3 h (Ea: À22% to À35%; SVR: À16% to À29%; all p < 0.05 vs. baseline) ( Table 4 , Figure 2B ).
The PVA was significantly and dose-dependently reduced versus baseline at 3 h, with the 25-, 50-, and 75-mg/kg/min dose infusions leading to mean decreases of 28% to 43% (Table 4, Figure 2B ). These reductions were partially preserved at 1 h post-infusion (data not shown). hsabbah1@hfhs.org.
Analysis of BMS-
